PIK3CA Mutations in Advanced or Recurrent Endometrial Cancer: An Exploratory Molecular Profiling From the Phase II MITO END-3 Study. (PubMed, JCO Precis Oncol) - Oct 17, 2026 - "In this post hoc analysis from the MITO END-3 trial, we confirmed the high frequency of PIK3CA mutations in EC, establishing this tumor as an ideal candidate for testing of PI3K inhibitors in clinical trials."
IO biomarker • Journal • MSI-H • P2 data • Retrospective data • Breast Cancer • Endometrial Cancer • Gynecologic Cancers • Microsatellite Instability • Oncology • Solid Tumor • ARID1A • MSI • PIK3CA • PTEN • TP53
|
|
Alberto Farolfi; Anna Fagotti; Anna Passarelli; Carmela Pisano; Claudia Andreetta; Clorinda Schettino; Daniela Califano; Daniela Russo; Domenica Lorusso; Elena Zafarana; Francesco Perrone; Giovanni Luca Scaglione; Jole Ventriglia; Laura Arenare; Maria Chiara Cannizzaro; Maria Teresa Perri; Michele Bartoletti; Rossella De Cecio; Sabrina Chiara Cecere; Sandro Pignata; Saverio Cinieri; Serafina Mammoliti; Simona Scalone; Tommaso Ambrosio; Ugo De Giorgi; Valentina Arcangeli
|